UBS Group Upgrades LifeStance Health Group (NASDAQ:LFST) to "Buy"

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was upgraded by equities researchers at UBS Group from a "neutral" rating to a "buy" rating in a report issued on Tuesday, MarketBeat.com reports. The firm currently has a $8.50 target price on the stock. UBS Group's price objective would suggest a potential upside of 43.82% from the company's previous close.

A number of other brokerages have also recently commented on LFST. William Blair restated an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. Canaccord Genuity Group initiated coverage on LifeStance Health Group in a research report on Thursday, April 3rd. They set a "buy" rating and a $8.00 target price on the stock. Finally, KeyCorp started coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.50.

LifeStance Health Group Stock Performance

LFST traded down $0.13 during trading hours on Tuesday, hitting $5.91. The stock had a trading volume of 2,731,120 shares, compared to its average volume of 1,592,747. LifeStance Health Group has a 1 year low of $4.64 and a 1 year high of $8.61. The company's fifty day simple moving average is $6.35 and its 200 day simple moving average is $7.15. The stock has a market cap of $2.30 billion, a PE ratio of -22.73 and a beta of 1.30. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19.

Insider Buying and Selling

In related news, insider Lisa K. Miller sold 18,845 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the transaction, the insider now directly owns 339,810 shares in the company, valued at $2,344,689. The trade was a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in LifeStance Health Group by 65.7% during the fourth quarter. SG Americas Securities LLC now owns 90,355 shares of the company's stock worth $666,000 after buying an additional 35,823 shares in the last quarter. JPMorgan Chase & Co. grew its position in LifeStance Health Group by 13.0% during the third quarter. JPMorgan Chase & Co. now owns 94,636 shares of the company's stock worth $662,000 after buying an additional 10,894 shares in the last quarter. Jennison Associates LLC grew its position in LifeStance Health Group by 278.4% during the fourth quarter. Jennison Associates LLC now owns 8,086,380 shares of the company's stock worth $59,597,000 after buying an additional 5,949,438 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in LifeStance Health Group during the fourth quarter worth about $128,000. Finally, Blue Trust Inc. lifted its stake in LifeStance Health Group by 124.4% during the fourth quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after purchasing an additional 2,122 shares during the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.